PMC:7079862 / 26339-26643 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"928","span":{"begin":257,"end":265},"obj":"Species"},{"id":"932","span":{"begin":49,"end":58},"obj":"Species"},{"id":"938","span":{"begin":283,"end":298},"obj":"Disease"}],"attributes":[{"id":"A928","pred":"tao:has_database_id","subj":"928","obj":"Tax:9606"},{"id":"A932","pred":"tao:has_database_id","subj":"932","obj":"Tax:11520"},{"id":"A938","pred":"tao:has_database_id","subj":"938","obj":"MESH:D001102"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The FLU-IVIG RCT found no overall effect of anti-influenza hyperimmune IVIG compared to placebo on the primary outcome measured by a six-point ordinal scale of clinical status on day 7, although antiviral and clinical benefits were noted in the subgroup of patients with influenza B virus infection [38]."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T14","span":{"begin":151,"end":156},"obj":"Body_part"}],"attributes":[{"id":"A14","pred":"uberon_id","subj":"T14","obj":"http://purl.obolibrary.org/obo/UBERON_0002542"}],"text":"The FLU-IVIG RCT found no overall effect of anti-influenza hyperimmune IVIG compared to placebo on the primary outcome measured by a six-point ordinal scale of clinical status on day 7, although antiviral and clinical benefits were noted in the subgroup of patients with influenza B virus infection [38]."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T176","span":{"begin":49,"end":58},"obj":"Disease"},{"id":"T177","span":{"begin":271,"end":280},"obj":"Disease"},{"id":"T178","span":{"begin":283,"end":298},"obj":"Disease"},{"id":"T179","span":{"begin":289,"end":298},"obj":"Disease"}],"attributes":[{"id":"A176","pred":"mondo_id","subj":"T176","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A177","pred":"mondo_id","subj":"T177","obj":"http://purl.obolibrary.org/obo/MONDO_0005812"},{"id":"A178","pred":"mondo_id","subj":"T178","obj":"http://purl.obolibrary.org/obo/MONDO_0005108"},{"id":"A179","pred":"mondo_id","subj":"T179","obj":"http://purl.obolibrary.org/obo/MONDO_0005550"}],"text":"The FLU-IVIG RCT found no overall effect of anti-influenza hyperimmune IVIG compared to placebo on the primary outcome measured by a six-point ordinal scale of clinical status on day 7, although antiviral and clinical benefits were noted in the subgroup of patients with influenza B virus infection [38]."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T197","span":{"begin":131,"end":132},"obj":"http://purl.obolibrary.org/obo/CLO_0001020"},{"id":"T198","span":{"begin":281,"end":282},"obj":"http://purl.obolibrary.org/obo/CLO_0001021"},{"id":"T199","span":{"begin":283,"end":288},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_10239"}],"text":"The FLU-IVIG RCT found no overall effect of anti-influenza hyperimmune IVIG compared to placebo on the primary outcome measured by a six-point ordinal scale of clinical status on day 7, although antiviral and clinical benefits were noted in the subgroup of patients with influenza B virus infection [38]."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T225","span":{"begin":195,"end":204},"obj":"Chemical"}],"attributes":[{"id":"A225","pred":"chebi_id","subj":"T225","obj":"http://purl.obolibrary.org/obo/CHEBI_22587"}],"text":"The FLU-IVIG RCT found no overall effect of anti-influenza hyperimmune IVIG compared to placebo on the primary outcome measured by a six-point ordinal scale of clinical status on day 7, although antiviral and clinical benefits were noted in the subgroup of patients with influenza B virus infection [38]."}

{"project":"LitCovid-sentences","denotations":[{"id":"T199","span":{"begin":0,"end":304},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The FLU-IVIG RCT found no overall effect of anti-influenza hyperimmune IVIG compared to placebo on the primary outcome measured by a six-point ordinal scale of clinical status on day 7, although antiviral and clinical benefits were noted in the subgroup of patients with influenza B virus infection [38]."}

{"project":"2_test","denotations":[{"id":"32040667-31582358-47981314","span":{"begin":300,"end":302},"obj":"31582358"},{"id":"T64369","span":{"begin":300,"end":302},"obj":"31582358"}],"text":"The FLU-IVIG RCT found no overall effect of anti-influenza hyperimmune IVIG compared to placebo on the primary outcome measured by a six-point ordinal scale of clinical status on day 7, although antiviral and clinical benefits were noted in the subgroup of patients with influenza B virus infection [38]."}